All Trials

A Phase 2a Trial of Immune Modulation in Combination With Ultrasound-mediated Blood Brain Barrier Opening in Patients With Newly Diagnosed Glioblastoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with newly diagnosed, IDH-wild type, MGMT-unmethylated GBM post-radiotherapy (ECOG 0–2) receive Sonocloud-9–mediated blood–brain barrier opening every 3 weeks synchronized with liposomal doxorubicin plus balstilimab (anti–PD-1) and botensilimab (Fc‑enhanced anti–CTLA‑4). Excludes prior immunotherapy, multifocal/not-coverable or posterior fossa disease, active autoimmune disease, and other major comorbidities.

ClinicalTrials.gov ID: NCT05864534

An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases (EBVision)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling children and adults with EBV-positive disorders who lack suitable first-line options or have relapsed/refractory disease, including PID/AID-associated EBV+ LPD, CNS-involved EBV+ PTLD, PTLD where rituximab/chemotherapy is inappropriate (including CD20‑negative), and rapidly progressive EBV+ sarcomas. Participants receive tabelecleucel, an allogeneic, partially HLA‑matched EBV‑specific cytotoxic T‑cell therapy targeting EBV antigens (EBNA/LMP), given IV on Days 1, 8, and 15 of 35‑day cycles until response or progression.

ClinicalTrials.gov ID: NCT04554914

A Phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced or metastatic soft tissue sarcoma of the extremities/body wall/scalp with at least one palpable or ultrasound‑guided injectable lesion receive intratumoural tigilanol tiglate (EBC‑46), a plant‑derived protein kinase C modulator that induces rapid vascular disruption and hemorrhagic necrosis for local tumor ablation. Single or multiple injections (up to 3.6 mg/m2) are evaluated for local ablation and systemic disease control, with RECIST responses assessed in Stage 2.

ClinicalTrials.gov ID: NCT05755113

A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: PSMA PET–positive metastatic castration‑resistant prostate cancer on continuous ADT after ≥1 ARSI; no PSMA‑negative lesions, with Part 3 requiring prior Lu‑177–PSMA (and allowing ≤1 prior taxane). Investigational therapy is Ac‑225 rosopatamab tetraxetan (225Ac‑J591), a PSMA‑targeted alpha‑emitting monoclonal antibody delivered in a single fractionated cycle (Day 1/15) at 45–60 kBq/kg, with randomized dose optimization in PSMA‑RT–naive patients and dose escalation/expansion in those post‑Lu‑177.

ClinicalTrials.gov ID: NCT06549465

A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Men with metastatic castration-resistant prostate cancer progressing on abiraterone (ECOG 0–1, on continuous ADT, no prior second‑generation AR inhibitor or mCRPC chemotherapy) are randomized to enzalutamide alone versus enzalutamide plus ZEN003694, an oral pan-BET bromodomain inhibitor (BRD2/3/4/BRDT) aiming to suppress AR/MYC-driven transcription. Two predefined cohorts (poor vs good prior abiraterone responders) are included; crossover from control at radiographic progression is allowed.

ClinicalTrials.gov ID: NCT04986423

Phase II Single Arm Study Testing SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Men With Hormone Sensitive Oligometastatic Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Men with hormone-sensitive oligometastatic prostate adenocarcinoma (1–3 SBRT-amenable lesions; prior definitive therapy; testosterone >125 ng/dL; PSA 0.5–50; PSADT <15 months; ECOG 0–2) receive metastasis-directed SBRT plus adenosine-axis modulation with quemliclustat (CD73 inhibitor) and etrumadenant (A2A/A2B receptor antagonist) followed by PD-1 blockade with zimberelimab. Aims to improve biochemical and radiographic control versus historical SBRT alone while deferring ADT.

ClinicalTrials.gov ID: NCT05915442

A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Men with metastatic castration-resistant prostate adenocarcinoma after at least one second-generation AR inhibitor (± prior taxane), castrate and ECOG 0–2, with a lesion accessible for transperineal intratumoral access/biopsy, and without visceral or brain metastases. Treatment involves partial oncolysis of a target lesion followed by intratumoral SV-102, a fixed-dose multi-agent immunotherapy (anti-CTLA-4, anti-PD-1, CD40 agonist, TLR9 agonist) designed to induce in situ vaccination; dose is escalated/optimized across cohorts.

ClinicalTrials.gov ID: NCT06533644

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults and children with biopsy-proven EBV-positive PTLD after solid organ or allogeneic HCT who have failed rituximab (± chemotherapy for SOT) receive tabelecleucel, an allogeneic, off‑the‑shelf EBV‑specific cytotoxic T‑cell therapy matched by HLA and infused on days 1, 8, and 15 of 35‑day cycles. Excludes T‑cell lymphomas, active/untreated CNS PTLD, significant GVHD, recent checkpoint inhibitors or EBV‑directed cell therapies, and requires measurable FDG‑avid disease and adequate organ function.

ClinicalTrials.gov ID: NCT03394365

A Phase 2 Study of NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Treatment-naïve, Metastatic Pancreatic Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Treatment-naïve adults with metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) receive modified FOLFIRINOX plus nivolumab with NC410, a recombinant LAIR-2–IgG1 Fc fusion protein that binds tumor collagen to block LAIR-1 inhibitory signaling and enhance T-cell activity; a second cohort adds ipilimumab. Excludes prior ICI/PDAC therapy and significant autoimmune/immunosuppression, with efficacy and safety endpoints including ORR, PFS, and toxicity.

ClinicalTrials.gov ID: NCT06941857

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Previously untreated adults with metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) are randomized to gemcitabine/nab-paclitaxel plus SBP-101 (ivospemin) versus placebo; SBP-101 is a polyamine analogue that modulates polyamine metabolism (inhibits ODC1 and S-adenosylmethionine decarboxylase) with preferential pancreatic uptake. Key exclusions include prior systemic therapy for metastasis, BRCA1/2 mutation if known, metformin use, retinopathy risk, active infections, and significant cardiopulmonary comorbidity.

ClinicalTrials.gov ID: NCT05254171